Tianci International, Inc. Reports Third Quarter 2025 Financial Results
Third Quarter 2025 Highlights:
About Tianci International, Inc.
Tianci International Inc., through its subsidiary Roshing, provides global logistics services specializing in ocean freight forwarding, including container and bulk goods shipping. Operating under an asset-light model, Roshing's logistics solutions are tailored to meet the diverse needs of its customers across the Asia-Pacific, including Japan, South Korea, and Vietnam. Beyond logistics, the company generates revenue from the sale of electronic parts and business consulting services. The company's mission is to provide customers with efficient, reliable, and safe shipping services that create value.
For more information, please visit the Company's website: tianci-ciit.com
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. The Company encourages investors to review other factors that may affect its future results that are discussed in the Company's filings with the U.S. Securities and Exchange Commission.
Contact Information
Michael Yip
[email protected]
SOURCE: Tianci International Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Freight market's ‘holding pattern' continues in July
The logistics industry continued to expand in July, but the transportation market remains stuck in a 'holding pattern,' according to a monthly survey of supply chain professionals. The Logistics Managers' Index – a diffusion index in which a reading above 50 indicates expansion while one below 50 signals contraction – returned a 52.6 reading for transportation capacity in the month. While up only 20 basis points from June, the subindex continued to show that any recovery in the freight cycle is unlikely to come from the supply side. Sentiment around transportation capacity has signaled growth for more than three years now. (The dataset returned neutral readings of 50 twice last year.) 'So long as this metric comes in above 50.0, it is unlikely that we will have a truly robust expansion in the freight market,' a Tuesday report said. Even with the modest capacity expansion, both transportation utilization (59.5) and transportation prices (63) were up in the month, 6.6 percentage points and 1 point, respectively. Most truckload carriers have advanced initiatives to better utilize equipment through the protracted downturn, including the removal of tractors from service. July marked the highest utilization reading since January (60.1), with firms upstream in the supply chain, like wholesalers, reporting expansion (60.7) versus no change (50) among downstream retailers. Transportation pricing has remained firmly in growth mode this year, averaging a monthly reading of 63.2. The pricing index again grew faster than the capacity index, suggesting the freight market is recovering, albeit slowly. (The pricing dataset has outpaced the capacity dataset by an average of 10 points in each month this year.) Respondents returned a 12-month-forward prediction of 75.5 for the pricing subindex. The overall LMI came in at 59.2 for the month, down 1.5 points from June. The all-time average for the dataset is 61.5. Smaller firms – companies with less than 1,000 employees – and upstream companies drove activity in the supply chain during July, with both reporting higher inventories. Overall, inventory levels (55.6) fell 4.2 points in the month. Smaller companies reported rapid expansion in inventory (64.8). Most of the smaller respondents are distributors, wholesalers and logistics service providers that reside in 'the middle mile of the supply chain,' between ports, manufacturers and retailers. Upstream firms saw expansion (58.5) versus contraction among downstream companies (47.6). A decline in stock levels among retailers was said to be 'due to the start-stop nature of tariffs.' The growth in inventories kept inventory costs (71.9) elevated, albeit 9 points lower than in June. Warehouse capacity (51.1) was up 3.3 points, crossing back into expansion territory. Capacity was 10 points tighter for smaller companies given their inventory additions. Warehouse utilization (59.4) fell 2.8 points while warehouse prices (68.3) were unchanged, maintaining a 'robust rate of expansion' in the month. Logistics real estate investment trust Prologis (NYSE: PLD) said on Monday that it is just a matter of time before market rents increase, noting well-capitalized, large-scale tenants are moving forward with leasing plans despite an uncertain macroeconomic backdrop. The LMI is a collaboration among Arizona State University, Colorado State University, Florida Atlantic University, Rutgers University and the University of Nevada, Reno, conducted in conjunction with the Council of Supply Chain Management Professionals. More FreightWaves articles by Todd Maiden: Beleaguered TL carrier Pamt Corp. names new CEO XPO sees 'massive runway' to push margins higher Schneider National not yet choosing sides on potential changes to railroad landscape The post Freight market's 'holding pattern' continues in July appeared first on FreightWaves. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Pharmacovigilance Automation Market Size, Key Players and Trends 2025
The pharmacovigilance automation market is gaining strong momentum worldwide, with projections indicating it will generate hundreds of millions in revenue between 2025 and 2034. Ottawa, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The pharmacovigilance automation market size growth is being driven by rising investments, ongoing innovation, and increasing demand across the healthcare and pharmaceutical sectors, a study published by Towards Healthcare a sister firm of Precedence Research. Get a free sample to explore key trends, market drivers, and growth insights: A key reason for this expansion is the tightening of global drug safety regulations and the need to better manage the growing number of adverse drug reactions. To meet these challenges, companies are turning to advanced technologies like artificial intelligence, natural language processing (NLP), and machine learning. These tools are helping automate tasks such as collecting, identifying, and analyzing adverse events making the process faster, more accurate, and cost-effective. Regionally, North America is leading the market thanks to heavy R&D spending by pharma companies and a strong digital healthcare infrastructure. Meanwhile, Asia Pacific is emerging as the fastest-growing region, driven by a high volume of clinical trials and a robust regulatory landscape. Key Takeaways North America is dominant in the pharmacovigilance automation market in 2024 with a 45% share. Asia Pacific is estimated to grow at the fastest CAGR from 2025 to 2035. By function, the case processing & reporting segment for the largest market revenue in 2024, with a 42% share. By function, the regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. By technology, the robotic process automation (RPA) segment is dominant in the market in 2024 with a 36% share. By technology, the natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. By deployment mode, the cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. By end user, the pharmaceutical & biotechnology companies segment is dominant in the market in 2024 with a 48% share. By end user, the academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Market Overview & Potential What is the Growth Potential Responsible for the Growth of the Pharmacovigilance Automation Market? The growth of the market is driven by the growing demand and increasing drug development, fueled by the expanding pharmaceutical industry's demand for safety monitoring systems, which in turn fuels the growth of the market. The rising adverse drug reactions monitoring due to increasing chronic diseases demands effective pharmacovigilance practices. Other key growth drivers are the regulatory stringency, technological advancement to automate the task and improve the accuracy, and to streamline the assessment boosts the growth and expansion of the market. What are the Growing Trends Associated with the Pharmacovigilance Automation Market? AI and Machine Learning: AI and ML are increasingly utilized to automate various tasks such as identifying adverse events, extracting data from unstructured sources like social media, and monitoring literature. Automated Case Processing: Organizations are swiftly implementing automation for case handling, including intake, triage, and analysis, resulting in quicker reporting and greater efficiency. Big Data Analytics: Pharmacovigilance is employing big data analytics to detect patterns and correlations within large datasets, supporting signal detection and risk management. Real-World Evidence (RWE): The use of real-world data information collected outside clinical trials is on the rise, with automation playing a vital role in managing and analyzing this data effectively. Remote Work and Collaboration: The pandemic has sped up remote work adoption, and automation tools are facilitating improved collaboration and communication among pharmacovigilance teams. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growing Challenge in the Pharmacovigilance Automation Market? The key challenge that limits the growth of the Asia Pacific bioplastics market is the lack of sufficient funding for pharmacovigilance activities, resulting in limited implementation of advanced automation solutions, which limits the growth of the market. Other key challenge the is the shortage of skilled professionals who are experts in pharmacovigilance and automation technologies, which is a challenge and hinders the growth and expansion of the market. Regional Analysis How did North America Dominate the Pharmacovigilance Automation Market in 2024? North America dominated the pharmacovigilance automation market share by 45% in 2024, with a 45% share, driven by early adoption of automation in healthcare, including PV, which effectively manages inventory, orders, and tracking, ensuring proper medicine delivery and reducing errors. The FDA's Adverse Event Reporting System (FAERS) supports market growth by tracking adverse drug reactions and medication errors. Advanced technology infrastructure, stringent FDA regulations, and growing AI adoption promote pharmacovigilance automation. Emphasis on real-time data analytics, electronic health records integration, and robust drug safety frameworks drives automated adverse event reporting and signal detection to enhance patient safety and regulatory compliance. Canada's focus on digital health transformation, Health Canada's regulatory support, and investment in AI-powered pharmacovigilance tools promote automation. Collaboration among healthcare providers, researchers, and tech companies accelerates real-world data utilization, improving adverse event monitoring and drug safety through streamlined, automated reporting systems. What Made Asia Pacific Significantly Grow in the Pharmacovigilance Automation Market in 2024? The Asia Pacific region is projected to experience the fastest growth during the forecast period. Its rise is fueled by rapid product launches in healthcare, increasing consumer expectations, and the expanding use of digital health technology. Ongoing healthcare transformation, supported by policies, infrastructure development, and public-private partnerships, positions APAC to become a global leader in digital health, thus propelling market growth of market growth. China's expanding pharmaceutical industry, government initiatives for digital health, and adoption of big data and AI technologies drive pharmacovigilance automation. The National Medical Products Administration encourages automation to enhance drug safety surveillance, leveraging vast healthcare data to improve adverse event detection and regulatory oversight. India's growing pharmaceutical sector, government policies supporting digital health, and increased AI integration promote pharmacovigilance automation. The Central Drugs Standard Control Organization encourages automated adverse event reporting to enhance patient safety. Collaborative efforts between government, industry, and academia drive the adoption of technology for efficient drug safety monitoring. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By function The case processing & reporting segment for the largest pharmacovigilance automation market revenue in 2024, with a 42% share. It provides data for investigating adverse effects, enabling the identification of new safety concerns and occasional assessment of the profit-to-challenge ratio for pharmaceutical use. It facilitates data exchange among stakeholders like patients, healthcare professionals, and authorities by sharing large volumes of safety information. Case reports play a key role in detecting new safety signals through the description of rare or delayed adverse effects that might not be observed in clinical trials. The regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. Automation in regulatory compliance ensures that medications and healthcare devices meet strict standards of quality, safety, and efficacy before market release. Agencies such as the FDA, EMA, and WHO enforce guidelines like GMP, GCP, and GDP throughout all stages of development and distribution. Following these guidelines is crucial for maintaining public trust and ensuring success in the medical industry. By technology The robotic process automation (RPA) segment is dominant in the pharmacovigilance automation market in 2024 with a 36% share. Robotic process automation (RPA) enhances operational efficiency by streamlining workflows, reducing risks, and minimizing delays and rework, which lowers operational costs. RPA offers privacy and security benefits, helps pharmaceutical companies reduce human errors, and improves data accuracy to support better decision-making. In pharmacovigilance, RPA is especially valuable for faster adverse effect response times. The natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. NLP has become essential in pharmacovigilance, a field focused on monitoring and preventing drug-related adverse effects. It efficiently manages vast amounts of unstructured data such as patient records and social media posts, which provide real-world insights into drug effects. NLP aids in regulatory compliance and accelerates reporting to health authorities. By deployment mode The cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. Cloud solutions deliver robust security features like data encryption, secure access protocols, and regular backups. As an emerging tool, cloud-based systems in pharmacovigilance support seamless data integration by providing internet-based storage, computing services, analytics, and software, thus enhancing efficiency. By end user, The pharmaceutical & biotechnology companies segment is dominant in the pharmacovigilance automation market in 2024 with a 48% share. Pharmacovigilance companies share core goals with government agencies: protecting patients from harm by detecting hidden drug complexities early, identifying risk factors, debunking false safety signals, and addressing benefit challenges. PV raises awareness among healthcare professionals and patients regarding contraindications, indications, doses, administration routes, and adverse effects. The academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Pharmacovigilance also hosts leading research platforms that improve patient care through informed prescribing and ensure government compliance. These collaborations with top industry players further fuel market growth. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Recent Developments in the Pharmacovigilance Automation Market In July 2025, Tata Consultancy Services (TCS) was recognized as a Leader in Everest Group's PEAK Matrix for Pharmacovigilance (PV) Operations services. The report emphasizes TCS's extensive pharmacovigilance offerings, including device complaint management, medical device product quality issues, medical device reporting, and post-market surveillance as key strengths. TCS's flagship ADD safety platform is notably highlighted for its touchless processing of individual case safety reports (ICSRs), featuring integrated quality control, smart signal detection, literature surveillance, and safety report generation. In September 2024, Truliant Consulting releases a white paper titled AI and Automation in Pharmacovigilance: Transformative Trends and Future Outlook. This paper results from an open survey aimed at pharmaceutical companies to explore their adoption of artificial intelligence (AI) within their Pharmacovigilance (PV) frameworks. Top Companies and Their Contributions to the Market Company Contributions & Offerings Oracle Corporation Provides cloud-based safety and pharmacovigilance solutions, integrating AI for automated case processing and compliance management. Veeva Systems Inc. Offers cloud software tailored for life sciences, including pharmacovigilance modules that streamline safety data management and reporting. ArisGlobal Develops end-to-end drug safety and pharmacovigilance platforms with automation, AI, and regulatory compliance features. IQVIA Combines real-world data analytics with automation to enhance signal detection, adverse event reporting, and clinical safety workflows. Cognizant Technology Solutions Delivers IT and BPO services focusing on automated pharmacovigilance processes, leveraging AI and machine learning for data accuracy. Accenture Provides digital transformation and AI-driven pharmacovigilance automation services to optimize safety data workflows globally. Genpact Specializes in AI-powered pharmacovigilance automation, improving adverse event case processing and regulatory reporting efficiency. Tata Consultancy Services (TCS) Offers integrated technology solutions automating safety data capture, analysis, and regulatory submissions in pharmacovigilance. Parexel International Corporation Provides clinical research and safety automation services, enhancing pharmacovigilance with AI-enabled case management and reporting tools. ICON plc Focuses on clinical research and drug safety automation, utilizing advanced analytics and automated adverse event monitoring systems. Pharmacovigilance Automation Market Key Players List Oracle Corporation Veeva Systems Inc. ArisGlobal IQVIA Cognizant Technology Solutions Accenture Genpact Tata Consultancy Services (TCS) Parexel International Corporation ICON plc Capgemini SE PharmaLex GmbH Indegene Pvt Ltd BioClinica (part of ERT) Infosys Limited HCL Technologies Ennov Tech Mahindra Zifo RnD Solutions NNIT A/S Browse More Insights of Towards Healthcare: Global Pharmaceutical & Compounding Market Outlook (2024–2034) The pharmaceutical and healthcare packaging sectors are undergoing notable transformation, supported by rising demand for personalized treatments, automation, and regulatory compliance. Here's a breakdown of key market trajectories: GCC Compounding Pharmacy MarketThe GCC compounding pharmacy market is witnessing a strong upward trend. Valued at USD 16.39 million in 2024, it is expected to reach approximately USD 40.26 million by 2034, growing at a CAGR of 9.27%. This growth is driven by the increasing need for tailored medications across the Gulf region. Global Non-Sterile Compounding Pharmacy MarketThe non-sterile compounding pharmacy market was estimated at USD 5.97 billion in 2024 and is set to almost double by 2034, reaching around USD 12.11 billion. With a CAGR of 7.34%, the market reflects expanding demand for dosage flexibility and patient-specific drug formulations. Global Pharmacy Automation MarketThe pharmacy automation market is advancing rapidly as healthcare systems adopt technologies to streamline dispensing and improve safety. Starting at USD 6.35 billion in 2024, the market is projected to reach USD 16.65 billion by 2034, growing at a CAGR of 10.12%. Global Compounding Pharmacy MarketThe global compounding pharmacy market stood at USD 13.19 billion in 2023 and is projected to climb to USD 22.91 billion by 2034. This steady growth, at a CAGR of 5.15%, is propelled by rising chronic disease prevalence and the need for customized drug therapies. Global Vials Used in Compounding Pharmacy MarketThe vials used in compounding pharmacy market is set for strong revenue growth over the forecast period. The market is expanding in response to higher demand for safe and precise medication containers, especially in sterile compounding. Global Biotechnology & Pharmaceutical Services MarketThe biotechnology and pharmaceutical services market is projected to grow from USD 76.51 billion in 2024 to around USD 130.56 billion by 2034, at a CAGR of 5.48%. The market benefits from increased outsourcing, R&D intensity, and regulatory support. Global Biopharmaceuticals CRO MarketThe biopharmaceuticals CRO (Contract Research Organization) market is on a robust growth path. With rising R&D and a push for cost efficiency, the market is expected to generate significant revenue gains through 2034. Global Pharmaceutical Spray Drying MarketThe pharmaceutical spray drying market is valued at USD 2.37 billion in 2024 and forecast to nearly double, reaching USD 4.93 billion by 2034. A CAGR of 7.67% reflects the increased use of this technology for enhancing bioavailability in drug formulations. Global Ready-to-Use Pharmaceutical Packaging MarketThe ready-to-use pharmaceutical packaging market was valued at USD 10.4 billion in 2024 and is anticipated to reach USD 20.97 billion by 2034. Growing at a CAGR of 7.24%, this market is shaped by demand for efficiency, sterility, and compliance. Global Pharmaceutical Secondary Packaging MarketThe pharmaceutical secondary packaging market is estimated at USD 43.11 billion in 2024 and is expected to grow to USD 69.45 billion by 2034. With a CAGR of 4.94%, this segment is critical for safety labeling, tracking, and brand protection. Segments Covered in The Report By Function Case Processing & Reporting Case Intake Medical Review Data Entry & Coding Signal Detection & Management Literature Screening Regulatory Compliance Automation Risk Management & Benefit-Risk Evaluation Report Submission & Distribution Quality Control & Reconciliation By Technology Robotic Process Automation (RPA) Artificial Intelligence (AI) & Machine Learning Natural Language Processing (NLP) Cloud-Based PV Platforms Rules-Based Automation Tools Intelligent Automation By Deployment Mode On-Premises Cloud-Based By End User Pharmaceutical & Biotechnology Companies Contract Research Organizations (CROs) Pharmacovigilance Service Providers Regulatory Agencies Academic & Research Institutions By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait To invest in our premium strategic solution and customized market report options, click here: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
3 hours ago
- Entrepreneur
GameRamp, Shortgun Games, and EON Space Labs Raise Funding for Growth
The below brands have announced their latest funding rounds. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. BITKRAFT Backs GameRamp With USD 5.4 Mn Pre‑Seed Funding GameRamp has raised USD 5.4 million in a pre‑seed funding round led by BITKRAFT Ventures, with participation from South Park Commons, Mixi, DeVC and other global angel investors. The funding will be used to expand the company's engineering and applied artificial intelligence teams in the United States and India. It will also accelerate the launch of two services, Sentinel and Grow. Sentinel is an AI platform that offers real‑time personalization of in‑game economies and monetization through reinforcement learning. Grow is designed as an embedded financing layer to give developers seamless access to capital. "Scaling new apps or games has increasingly become hyper competitive. Developers need to excel in many areas beyond the core product experience. What if we could accelerate this with AI," said Vivek Ramachandran, Co‑founder and chief executive officer of GameRamp. "It is not only about improving existing processes, but enabling a new level of experimentation and insight. Our partners in Vietnam, India and Turkey are already seeing encouraging results." Anuj Tandon, Partner at BITKRAFT Ventures, said GameRamp combines expertise in machine learning, product growth and investment. "Their focus on developer outcomes is evident from the strong customer engagement. This positions them to change how consumer internet entrepreneurs grow in emerging markets." Founded by Vivek Ramachandran and Sashank Vandrangi, GameRamp is headquartered in San Francisco with a research and development hub in Bengaluru. Shortgun Games Secures USD 1 Mn to Develop Cinematic Shooter Shortgun Games has raised USD 1 million in seed funding from angel investors to advance development of a cinematic third‑person shooter aimed at global audiences. The funds will be directed toward creating a polished vertical slice, a playable five‑to‑eight‑minute version showcasing the game's mechanics, narrative, and visual style. The studio operates primarily from India with select international collaborators and plans to seek an additional USD 5 million in its next funding round to move into full production. "This funding will allow us to go beyond prototypes and deliver a polished vertical slice that encapsulates the heart of our game," said founder Vidhit Mehta. "We are focusing on quality‑first development, refining systems, narrative tone, and gameplay depth." Shortgun Games was founded by the original creators of Rogue Heist, including Vidhit Mehta, Ashish Beuria, and Neha Hooda. The studio's debut project is a console‑grade, narrative‑driven shooter exploring themes of identity, instinct, and transformation. The team recently collaborated with Bollywood action director Vicky Arora, known for films such as URI, RRR, and TANAAV, to ensure combat sequences combine technical precision with storytelling depth. Managing director Jeet Chandan said the goal is to create a flagship intellectual property blending cinematic storytelling, emotional choice, and strong gameplay mechanics. Game director Ashish Beuria added that this phase offers the freedom to test bold ideas and challenge expectations for Indian‑made shooters. EON Space Labs Raises USD 1.2 Mn for Optical Payload Expansion EON Space Labs has raised USD 1.2 million in a pre-Series A funding round from MGF Kavachh, with HHV Advanced Technologies joining as an investor and strategic partner. The Hyderabad-based deeptech startup will deploy the funds to scale manufacturing of its electro-optical and infrared payloads, expand its engineering team, and launch upcoming products. Key developments include the planned release of MIRA, which the company says will be India's lightest high-resolution space telescope, and four new LUMIRA EO/IR systems for drones and ground-based platforms. "Our collaboration will help advance India's capabilities in miniaturised optics, high-resolution imaging, and dual-use payload systems," said Sanjay Kumar, Co-founder of EON Space Labs. Punit Badeka, also a co-founder, added that the aim is to make high-quality Earth observation tools more accessible. Founded in 2022 by Sanjay Kumar, Punit Badeka, and Manoj Kumar Gaddam, the IIT Madras-incubated startup develops miniaturised imaging systems for satellites, drones, aerial platforms, and fixed ground stations. Its products are designed to be up to three times lighter than conventional payloads while maintaining image quality. The company is also working on global partnerships and has secured commercial orders after proof-of-concept trials.
